Bioproduction in China has gone beyond niche science and become an industrial priority. The industry has become one of the priority directions of the 15th Five-Year Plan, and the market volume has already reached 1.1 trillion yuan. China considers it a critically important growth driver (source).
Bioproduction is the industrial use of biological systems for the production of high value-added products. It connects biological systems (microorganisms, cell cultures, enzymes) with industrial processes and equipment, allowing the production of biomaterials, biomolecules and other valuable products.
For foreign business in China, several directions are opening up: supply of high-tech equipment (bioreactors, sensor systems, laboratory automation); solutions for genetic modification of strains and modern fermentation technologies; development of new food ingredients, alternative proteins and eco-friendly biomaterials. It is better to enter the market through specialized clusters: synthetic biology is concentrated in Shenzhen, Wuxi and Suzhou, biopharmaceuticals and cell therapy — in Shanghai and Beijing, marine bioproduction — in Hainan and Qingdao.
The main difficulty for foreign companies is the balance between great opportunities and strict state control: rules of biosafety, work with genetic resources, protection of intellectual property and export restrictions. It is most reliable to enter the industry through partnership formats: joint ventures, joint R&D projects, licensing agreements and technology transfer.
Who is affected: foreign equipment manufacturers, biotechnology companies, investors and foreign trade participants.